HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Whitfield, J. B. Search for Related Content PubMed PubMed Citation Articles by Whitfield, J. B. Related Collections Molecular Diagnostics and Genetics Evidence Based Laboratory Medicine and Test Utilization Proteomics and Protein Markers Lipids, Lipoproteins, and Cardiovascular Risk Factors Endocrinology and Metabolism

Serum -Glutamyltransferase and Risk of Disease

Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia, Fax 61-2-9515-7931, E-mail John.Whitfield@email.cs.nsw.gov.au

The first 20% of the full text of this article appears below.

Serum -glutamyltransferase (GGT) has long been used as a liver function test and a marker of excessive alcohol use; in recent years our knowledge of GGT’s physiological functions has expanded and several important epidemiological associations have been reported. The paper by Ryu et al. in this issue of Clinical Chemistry (1) extends the range of conditions predicted by GGT to include chronic kidney disease (CKD). Such prospective associations between GGT and disease raise issues in both pure and applied science; first, the pathological significance of the wide range of GGT–disease risk associations, and second, the effects that this information may have on the clinical or preventive use of GGT determinations.

CKD is an increasingly common and important condition (2). Existing laboratory markers include glomerular filtration rate estimated from serum creatinine, sex, age, and race (eGFR), and the presence of proteinuria. Because CKD tends to progress, these markers also have predictive value. Defining the pathological role of GGT in CKD will require more investigation. GGT may be a marker of the pathological process or even a contributor, but in either case, GGT is a novel predictor of CKD that could contribute to early intervention and improved outcomes.

The study by Ryu et al. (1) was carried out on a cohort of Korean men given a regular health check as part of their employment and followed for up to . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				E. Szajli, T. Feher, and K. F. Medzihradszky Investigating the Quantitative Nature of MALDI-TOF MS Mol. Cell. Proteomics, December 1, 2008; 7(12): 2410 - 2418. [Abstract] [Full Text] [PDF]

				D.-H. Lee, M. D. Gross, M. W. Steffes, and D. R. Jacobs Jr Is Serum Gamma-Glutamyltransferase a Biomarker of Xenobiotics, Which Are Conjugated by Glutathione? Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): e26 - e28. [Full Text] [PDF]

				S. W. Leonard, J. D. Joss, D. J. Mustacich, D. H. Blatt, Y. S. Lee, and M. G. Traber Effects of vitamin E on cholesterol levels of hypercholesterolemic patients receiving statins Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2257 - 2266. [Abstract] [Full Text] [PDF]

				A. T. Murphy, D. R. Witcher, P. Luan, and V. J. Wroblewski Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry Blood, August 1, 2007; 110(3): 1048 - 1054. [Abstract] [Full Text] [PDF]

				I. Vanhorebeek, L. Langouche, and G. Van den Berghe Tight Blood Glucose Control With Insulin in the ICU: Facts and Controversies Chest, July 1, 2007; 132(1): 268 - 278. [Abstract] [Full Text] [PDF]